The health care industry is taking a stand against the maker of EpiPen
Share Now on:
As we all know, the maker of EpiPen, Mylan, has engaged in price gouging. But this week, the larger health care industry sent a strong message that they are not going to stand for it. On Wednesday, Cigna announced it would only cover the generic version of EpiPen. On Thursday, CVS announced a deal with an EpiPen competitor that could hurt Mylan’s generic sales. It’s a strange and unusual kind of pushback. The kind we rarely see in the health care industry.
Click the above audio player to hear the full story.
As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.
Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.
Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.
Thanks to our
Your support keeps us going strong, even through